# US 2003/0216474 A1 · Method of using prostacyclin to treat respiratory syncytial virus infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216474 A1
- Document ID: US20030216474A1
- Status: Published application
- Kind: A1
- Application number: 10/389,295
- Filed: 2003-03-14
- Published: 2003-11-20
- Earliest claimed: 2002-03-15
- Assignees: Vanderbilt University
- Inventors: Ray Stokes Peebles JR.; Koichi Hashimoto; Barney S. Graham
- Web page: https://patentgrep.com/patent/US20030216474A1

## CPC

- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention discloses methods and a kit for treating a respiratory syncytial virus infection. The method comprises providing an infection modulator, and administering a therapeutically effective amount of the infection modulator, wherein the respiratory syncytial virus infection is suppressed or precluded. The kit for suppressing a respiratory syncytial virus infection comprises an infection modulator, an applicator, and a set of instructions.

## Claims

### Claim 1

A method of suppressing a respiratory syncytial virus infection, comprising:
providing an individual having characteristics which increase the probability of severe symptoms due to a respiratory syncytial virus infection;
providing an infection modulator; and
administering a therapeutically effective amount of the infection modulator, wherein the respiratory syncytial virus infection is suppressed.

### Claim 2 (depends on 1)

The method of claim 1, further comprising determining that the respiratory syncytial virus infection is suppressed.

### Claim 3 (depends on 2)

The method of claim 2, wherein determining that the respiratory syncytial virus infection is suppressed further comprises identifying a level of a molecular derivative in a biological sample of the individual.

### Claim 4 (depends on 1)

The method of claim 1, wherein the infection modulator further comprises epoprostenol.

### Claim 5 (depends on 4)

The method of claim 4 wherein administering further comprises administering intravenously.

### Claim 6 (depends on 5)

The method of claim 5, wherein administering a therapeutically effective amount of the infection modulator further comprises administering from about 10 ng/kg/min to about 15 ng/kg/min of the infection modulator.

### Claim 7 (depends on 1)

The method of claim 1, wherein the infection modulator further comprises UT-15.

### Claim 8 (depends on 7)

The method of claim 7, wherein administering further comprises administering with a method selected from a group consisting of intravenous, subcutaneous, subcutaneous catheter, and micro-infusion pump.

### Claim 9 (depends on 7)

The method of claim 7, wherein administering a therapeutically effective amount of the infection modulator further comprises administering from about 5 ng/kg/min to about 20 ng/kg/min of the infection modulator.

### Claim 10 (depends on 1)

The method of claim 1, wherein the infection modulator further comprises iloprost.

### Claim 11 (depends on 10)

The method of claim 10, wherein administering further comprises administering with a method selected from a group consisting of intravenous, oral, and aerosol.

### Claim 12 (depends on 11)

The method of claim 11, wherein the aerosol is administered at least six times per 24 hour period.

### Claim 13 (depends on 10)

The method of claim 10, wherein administering a therapeutically effective amount of the infection modulator further comprises administering from about 2 ng/kg/min to about 5 ng/kg/min of the infection modulator.

### Claim 14 (depends on 1)

The method of claim 1, wherein the infection modulator further comprises beraprost.

### Claim 15 (depends on 14)

The method of claim 14, wherein administering further comprises ingesting the beraprost orally.

### Claim 16 (depends on 15)

The method of claim 15, wherein administering a therapeutically effective amount of the infection modulator further comprises administering from about 60 micrograms/day to about 180 micrograms/day of the infection modulator.

### Claim 17

A method of treating respiratory syncytial virus in an individual in need thereof comprising administering to the patient a therapeutically effective amount of a prostacyclin analog.

### Claim 18

A respiratory syncytial virus infection suppression kit, comprising:
an infection modulator;
an applicator; and
a package containing the infection modulator and the applicator.

### Claim 19 (depends on 18)

The kit of claim 18, wherein the infection modulator is selected from a group consisting of prostacyclin, epoprostenol, UT-15, iloprost, and beraprost.

### Claim 20 (depends on 18)

The kit of claim 18, wherein the applicator is selected from a group consisting of intravenous kit, and surgical needle.
